BAX and urinary bladder carcinoma: We believe that analysis of molecular markers such as BAX, BCL2, CD40 and CD40L may prove valuable in identifying patients with poor prognosis bladder cancers who may benefit from aggressive treatment and this should be considered in future trial design.